Search

Your search keyword '"Pongas, Georgios"' showing total 45 results
Start Over Author "Pongas, Georgios"
45 results on '"Pongas, Georgios"'

1. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial

Author

Alderuccio, Juan Pablo, Alencar, Alvaro J, Schatz, Jonathan H, Kuker, Russ A, Pongas, Georgios, Reis, Isildinha M, Lekakis, Lazaros J, Spiegel, Jay Y, Sandoval-Sus, Jose, Beitinjaneh, Amer, Stanchina, Michele D, Trabolsi, Asaad, Lossos, Izidore S, Rosenblatt, Joseph D, Lessen, David S, and Moskowitz, Craig H

Published
2025
Full Text
View/download PDF

2. Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

Author

Samples, Laura, Voutsinas, Jenna, Fakhri, Bita, Khajavian, Sirin, Spurgeon, Stephen, Stephens, Deborah, Skarbnik, Alan, Mato, Anthony, Broome, Catherine, Gopal, Ajay, Smith, Stephen, Lynch, Ryan, Rainey, Magdalena, Kim, Myung Sun, Barrett-Campbell, Odeth, Hemond, Emily, Tsang, Mazie, Ermann, Daniel, Malakhov, Nikita, Rao, Danielle, Shakib-Azar, Mehrdad, Morrigan, Beth, Chauhan, Ayushi, Plate, Thomas, Gooley, Ted, Ryan, Kellie, Lansigan, Frederick, Hill, Brian, Pongas, Georgios, Parikh, Sameer A., Roeker, Lindsey, Allan, John N., Cheng, Richard, Ujjani, Chaitra, and Shadman, Mazyar

Published
2024
Full Text
View/download PDF

3. Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia

Author

Ujjani, Chaitra, Gooley, Ted A., Spurgeon, Stephen E., Stephens, Deborah M., Lai, Catherine, Broome, Catherine M., O’Brien, Susan, Zhu, Haiying, Laing, Kerry J., Winter, Allison M., Pongas, Georgios, Greninger, Alexander L, Koelle, David M., Siddiqi, Tanya, Davids, Matthew S., Rogers, Kerry A., Danilov, Alexey V., Sperling, Amy, Tu, Brian, Sorensen, Tyler, Launchbury, Kelsey, Burrow, Carlissa J., Quezada, Genesis, Hill, Joshua A., Shadman, Mazyar, and Thompson, Philip A.

Published
2023
Full Text
View/download PDF

4. Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies.

Author

Bravo-Gonzalez, Andres, Alasfour, Maryam, Soong, Deborah, Noy, Jose, and Pongas, Georgios

Subjects
THERAPEUTIC use of antineoplastic agents, PROTEIN kinase inhibitors, CHRONIC lymphocytic leukemia, DRUG resistance in cancer cells, NON-Hodgkin's lymphoma, DRUG approval, LYMPHOPROLIFERATIVE disorders, B cell lymphoma
Abstract

Simple Summary: Bruton's tyrosine kinase inhibitors (BTKi) have revolutionized the treatment of various B-cell lymphoid malignancies. However, acquisition of resistance to BTKi has emerged as an important clinical challenge. Herein, we provide a detailed review, describing the clinical trials that led to the FDA approval of the BTK inhibitors for management of Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL) and Waldenstrom Macroglobulinemia (WM). We describe the mechanism of intrinsic and extrinsic resistance to the BTKi with main emphasis on the functional description of BTK mutations in CLL. Finally, we review the latest updates of the PROTACs BTK degraders, an evolving treatment modality for the management of the BTKi refractory B-cell malignancies. B-cell lymphoid malignancies are a heterogeneous group of hematologic cancers, where Bruton's tyrosine kinase (BTK) inhibitors have received FDA approval for several subtypes. The first-in-class covalent BTK inhibitor, Ibrutinib, binds to the C481 amino acid residue to block the BTK enzyme and prevent the downstream signaling. Resistance to covalent BTK inhibitors (BTKi) can occur through mutations at the BTK binding site (C481S) but also other BTK sites and the phospholipase C gamma 2 (PLCγ2) resulting in downstream signaling. To bypass the C481S mutation, non-covalent BTKi, such as Pirtobrutinib, were developed and are active against both wild-type and the C481S mutation. In this review, we discuss the molecular and genetic mechanisms which contribute to acquisition of resistance to covalent and non-covalent BTKi. In addition, we discuss the new emerging class of BTK degraders, which utilize the evolution of proteolysis-targeting chimeras (PROTACs) to degrade the BTK protein and constitute an important avenue of overcoming resistance. The moving landscape of resistance to BTKi and the development of new therapeutic strategies highlight the ongoing advances being made towards the pursuit of a cure for B-cell lymphoid malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study

Author

Samples, Laura, primary, Voutsinas, Jenna M., additional, Fakhri, Bita, additional, Khajavian, Sirin, additional, Spurgeon, Stephen E., additional, Stephens, Deborah M., additional, Skarbnik, Alan P, additional, Mato, Anthony R, additional, Broome, Catherine, additional, Gopal, Ajay K., additional, Smith, Stephen D, additional, Lynch, Ryan C, additional, Rainey, Magdalena A, additional, Kim, Myung Sun, additional, Barrett-Campbell, Odeth, additional, Hemond, Emily, additional, Tsang, Mazie, additional, Ermann, Daniel A., additional, Malakhov, Nikita, additional, Rao, Danielle, additional, Shakib-Azar, Mehrdad, additional, Morrigan, Beth, additional, Chauhan, Ayushi, additional, Plate, Thomas, additional, Gooley, Ted A., additional, Ryan, Kellie, additional, Lansigan, Frederick, additional, Hill, Brian T., additional, Pongas, Georgios, additional, Parikh, Sameer A, additional, Roeker, Lindsey Elizabeth, additional, Allan, John N, additional, Cheng, Richard, additional, Ujjani, Chaitra, additional, and Shadman, Mazyar, additional

Published
2024
Full Text
View/download PDF

9. Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia

Author

Ujjani, Chaitra S, primary, Gooley, Ted A, additional, Spurgeon, Stephen E., additional, Stephens, Deborah M., additional, Lai, Catherine, additional, Broome, Catherine M., additional, O'Brien, Susan M., additional, Zhu, Haiying, additional, Laing, Kerry J, additional, Winter, Allison M, additional, Pongas, Georgios, additional, Greninger, Alexander L, additional, Koelle, David M, additional, Siddiqi, Tanya, additional, Davids, Matthew S., additional, Rogers, Kerry A., additional, Danilov, Alexey V, additional, Sperling, Amy L, additional, Tu, Brian, additional, Sorensen, Tyler, additional, Launchbury, Kelsey M, additional, Burrow, Carlissa J, additional, Quezada, Genesis, additional, Hill, Joshua A., additional, Shadman, Mazyar, additional, and Thompson, Philip A, additional

Published
2022
Full Text
View/download PDF

11. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Wills, Beatriz, primary, Ganesan, Nivetha, additional, Shah, Gunjan L., additional, Wong, Phillip, additional, Argyropoulos, Kimon V., additional, Sen, Filiz, additional, Dogan, Ahmet, additional, Straus, David J., additional, Noy, Ariela, additional, Kumar, Anita, additional, Schoder, Heiko, additional, Michaud, Laure, additional, Palomba, Maria Lia, additional, Falchi, Lorenzo, additional, Lahoud, Oscar B, additional, Hamlin, Paul A., additional, Yahalom, Joachim, additional, Johnson, William T., additional, Zelenetz, Andrew D., additional, Intlekofer, Andrew M., additional, Owens, Colette, additional, Batlevi, Connie Lee, additional, Hamilton, Audrey, additional, Caron, Philip C, additional, Horwitz, Steven M., additional, Galasso, Natasha, additional, Hancock, Helen, additional, Davey, Theresa, additional, Santarosa, Alayna, additional, Perez, Leslie, additional, Capadona, Charisse, additional, Munayirji, Brittney, additional, Matasar, Matthew J., additional, Pongas, Georgios, additional, Casper, Ellie, additional, Salles, Gilles, additional, Moskowitz, Craig H., additional, Vardhana, Santosha, additional, and Moskowitz, Alison J., additional

Published
2022
Full Text
View/download PDF

12. T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

Author

Moskowitz, Alison J., primary, Shah, Gunjan, additional, Schöder, Heiko, additional, Ganesan, Nivetha, additional, Hancock, Helen, additional, Davey, Theresa, additional, Perez, Leslie, additional, Sohail, Samia, additional, Santarosa, Alayna, additional, Capadona, Charisse, additional, Munayirji, Brittney, additional, Kumar, Anita, additional, Lahoud, Oscar, additional, Batlevi, Connie, additional, Hamlin, Paul, additional, Straus, David J., additional, Owens, Colette, additional, Caron, Philip, additional, Intlekofer, Andrew, additional, Hamilton, Audrey, additional, Horwitz, Steven, additional, Falchi, Lorenzo, additional, Johnson, William, additional, Palomba, Lia, additional, Noy, Ariela, additional, Matasar, Matthew, additional, Pongas, Georgios, additional, Salles, Gilles, additional, Vardhana, Santosha, additional, Sanin, Beatriz Wills, additional, Yahalom, Joachim, additional, Dogan, Ahmet, additional, Zelenetz, Andrew, additional, and Moskowitz, Craig H., additional

Published
2022
Full Text
View/download PDF

17. Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma

Author

Pongas,Georgios and Cheson,Bruce

Subjects
Targets and Therapy [Blood and Lymphatic Cancer]
Abstract

Georgios Pongas,1 Bruce Cheson2 1Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA; 2Lymphoma Research Foundation, North Bethesda, MD, USACorrespondence: Bruce Cheson Email bdcheson@gmail.comAbstract: Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), including the PI3Kδ inhibitor umbralisib and the chimeric antigen receptor–T-cell therapy (CAR-T) axicabtagene ciloleucel. Herein, we present the latest advances in the management of FL, discussing the recently approved therapies in the relapsed and refractory (R/R) setting and various new therapeutic modalities that have the potential to change the treatment landscape and natural history of R/R FL.Keywords: bispecific antibodies, BsAbs, chimeric antigen receptor – T cell therapies, CAR-T, lenalidomide

Published
2021

18. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Moskowitz, Alison J., primary, Shah, Gunjan, additional, Schöder, Heiko, additional, Ganesan, Nivetha, additional, Drill, Esther, additional, Hancock, Helen, additional, Davey, Theresa, additional, Perez, Leslie, additional, Ryu, Sunyoung, additional, Sohail, Samia, additional, Santarosa, Alayna, additional, Galasso, Natasha, additional, Neuman, Rachel, additional, Liotta, Brielle, additional, Blouin, William, additional, Kumar, Anita, additional, Lahoud, Oscar, additional, Batlevi, Connie L., additional, Hamlin, Paul, additional, Straus, David J., additional, Rodriguez-Rivera, Ildefonso, additional, Owens, Colette, additional, Caron, Philip, additional, Intlekofer, Andrew M., additional, Hamilton, Audrey, additional, Horwitz, Steven M., additional, Falchi, Lorenzo, additional, Joffe, Erel, additional, Johnson, William, additional, Lee, Christina, additional, Palomba, M. Lia, additional, Noy, Ariela, additional, Matasar, Matthew J., additional, Pongas, Georgios, additional, Salles, Gilles, additional, Vardhana, Santosha, additional, Sanin, Beatriz Wills, additional, von Keudell, Gottfried, additional, Yahalom, Joachim, additional, Dogan, Ahmet, additional, Zelenetz, Andrew D., additional, and Moskowitz, Craig H., additional

Published
2021
Full Text
View/download PDF

21. Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Author

Sawalha, Yazeed, Sarosiek, Shayna R, Welkie, Rina Li, Seif, Sherif, Thapa, Shrinjaya, Zanwar, Saurabh, Cahill, Kirk, Treitman, Rachel, Shah, Haikoo, Arora, Shagun, Pongas, Georgios, Winter, Allison, Major, Ajay, Riedell, Peter A., Palomba, Maria Lia, Kapoor, Prashant, Grajales-Cruz, Ariel F., Shain, Kenneth H., Thomas, Sheeba K., and Castillo, Jorge J.

Published
2023
Full Text
View/download PDF

22. Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Author

Ujjani, Chaitra S, Gooley, Ted, Siddiqi, Tanya, Stephens, Deborah M., Broome, Catherine, Spurgeon, Stephen E, Lai, Catherine, Winter, Allison, Pongas, Georgios, Greninger, Alex, Hill, Joshua A., O'Brien, Susan M., Davids, Matthew S, Rogers, Kerry A, Danilov, Alexey, Quezada, Genesis, Zhu, Haiying, Sperling, Amy, Sorensen, Tyler, Launchbury, Kelsey, Wierda, William G., Shadman, Mazyar, and Thompson, Philip A.

Published
2023
Full Text
View/download PDF

25. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Moskowitz, Alison J., primary, Shah, Gunjan, additional, Schöder, Heiko, additional, Ganesan, Nivetha, additional, Hancock, Helen, additional, Davey, Theresa, additional, Sohail, Samia, additional, Santarosa, Alayna, additional, Pomerantz, Lauren, additional, Jarjies, Christine, additional, Galasso, Natasha, additional, Neuman, Rachel, additional, Kumar, Anita, additional, Lahoud, Oscar B, additional, Batlevi, Connie Lee, additional, Hamlin, Paul A., additional, Straus, David J., additional, Rodriguez-Rivera, Ildefonso, additional, Owens, Colette, additional, Caron, Philip, additional, Intlekofer, Andrew M., additional, Hamilton, Audrey, additional, Horwitz, Steven M., additional, Falchi, Lorenzo, additional, Joffe, Erel, additional, Palomba, Maria Lia, additional, Noy, Ariela, additional, Matasar, Matthew J, additional, Pongas, Georgios, additional, Vardhana, Santosha, additional, von Keudell, Gottfried R., additional, Yahalom, Joachim, additional, Zelenetz, Andrew D, additional, and Moskowitz, Craig H., additional

Published
2020
Full Text
View/download PDF

27. Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate.

Author

Costa, Philippos Apolinario, Espejo-Freire, Andrea Patricia, Fan, Kenneth Chen, Albini, Thomas Arno, and Pongas, Georgios

Subjects
ANTIBODY-drug conjugates, IRIDOCYCLITIS, EYE pain, ANAPLASTIC large-cell lymphoma
Abstract

To our knowledge, this is the first case report of panuveitis associated with BV described in the literature and the second report of uveitis during BV therapy [[3]]. Brentuximab vedotin (BV) is an antibody-drug conjugate composed of an anti-CD30 monoclonal antibody conjugated through a linker to the microtubule disturbing agent monomethyl auristatin E (MMAE). The improvement of the ocular symptoms following the BV discontinuation in the absence of other etiologies that could explain the panuveitis makes BV a likely culprit. [Extracted from the article]

Published
2022
Full Text
View/download PDF

42. Activity of Deferasirox in Mucorales: Influences of Species and Exogenous Iron

Author

Lewis, Russell E., Pongas, Georgios N., Albert, Nathaniel, Ben-Ami, Ronen, Walsh, Thomas J., and Kontoyiannis, Dimitrios P.

Abstract

ABSTRACTDifferences in deferasirox susceptibility among members of the order Mucoralesare unknown. Here we show that Cunninghamellabertholletiae(four isolates) and Mucorspecies (five isolates) display higher deferasirox MICs and minimal fungicidal concentrations compared to Rhizopusspecies (six isolates). Exogenous iron further attenuated the deferasirox susceptibility of Mucoralesisolates with low MICs. Vital staining revealed damage to subapical compartments in susceptible strains.

Published
2010
Full Text
View/download PDF

43. Invasive Mold Infections in Pediatric Cancer Patients Reflect Heterogeneity in Etiology, Presentation, and Outcome: A 10-Year, Single-Institution, Retrospective Study

Author

Georgiadou, Sarah P., Pongas, Georgios, Fitzgerald, Nancy E., Lewis, Russell E., Rytting, Michael, Marom, Edith M., and Kontoyiannis, Dimitrios P.

Abstract

Background. There is scarcity of data regarding invasive mold infections (IMIs) in children with cancer. Methods. We retrospectively identified patients (18 years old or younger) with malignant disease who developed proven or probable IMIs (European Organization for Research on the Treatment of Cancer/Mycoses Study Group criteria) during a 10-year period (1998-2008). We reviewed their risk factors and clinical characteristics and assessed their crude mortality rates and treatment outcomes 12 weeks after IMI diagnosis. Results. Forty-eight patients (30 males) were identified, 30 (63%) of whom had a proven IMI. The most prevalent mold were Aspergillus species (40%), followed by Mucorales (20%) and Fusarium species (11%). Acute leukemia was the most common underlying malignancy (39 patients, [81%]). Twenty-three (59%) of them had refractory leukemia. Neutropenia was present at the day of IMI diagnosis in 67% of the patients. Sixty-two percent of the patients received prior corticosteroids. The dominant site of infection was the lungs (79%), followed by skin (29%) and sinuses (10%). Seventy-one percent of patients had radiological findings suggestive of fungal pneumonia (either nodules or masses). The mainstay of antifungal therapy was a lipid formulation of amphotericin B. Antifungal therapy resulted in 54% response rate (33% complete) at 12 weeks. The crude 12-week mortality rate was 31%. Logistic regression analysis demonstrated that monocytopenia (P = .013), malnutrition (P = .012), and intensive care admission in the month prior to IMI diagnosis (P = .027) were risk factors for death within 12 weeks. Conclusions. Although Aspergillus spp. was the most common mold in our pediatric cancer population, the epidemiology of the IMIs was diverse. Adults and children share similar risk factors for and epidemiology of IMIs.

Published
2012
Full Text
View/download PDF

45. Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations.

Author

Myers CS, Williams E, Cornejo CB, Pongas G, Toomey NL, Sanches JA, Battistella M, Mo S, Pulitzer M, Moskaluk CA, Bhagat G, Ofori K, Davick JJ, Servitje O, Miyashiro D, Climent F, Ringbloom K, Duenas D, Law C, Zambrano SC, Malpica L, Beltran BE, Castro D, Barreto L, Brites C, Chapman JR, Choi J, Gru AA, and Ramos JC

Subjects
Humans, Genomics methods, Prognosis, Male, Adult, HTLV-I Infections genetics, HTLV-I Infections virology, Female, Middle Aged, Leukemia-Lymphoma, Adult T-Cell genetics, Leukemia-Lymphoma, Adult T-Cell virology, Leukemia-Lymphoma, Adult T-Cell mortality, Human T-lymphotropic virus 1 genetics, Mutation
Abstract

Adult T-cell leukemia-lymphoma (ATLL) is an aggressive malignancy driven by human T-cell leukemia virus type 1 (HTLV-1). Although patients from the Western hemisphere (Afro-Caribbean and South American) face worse prognoses, our understanding of ATLL molecular drivers derives mostly from Japanese studies. We performed multi-omic analyses to elucidate the genomic landscape of ATLL in Western cohorts. Recurrent deletions and/or damaging mutations involving FOXO3, ANKRD11, DGKZ, and PTPN6 implicate these genes as potential tumor suppressors. RNA-sequencing, published functional data and in vitro assays support the roles of ANKRD11 and FOXO3 as regulators of T-cell proliferation and apoptosis in ATLL, respectively. Survival data suggest that ANKRD11 mutation may confer a worse prognosis. Japanese and Western cohorts, in addition to acute and lymphomatous subtypes, demonstrated distinct molecular patterns. GATA3 deletion was associated with chronic cases with unfavorable outcomes. IRF4 and CARD11 mutations frequently emerged in relapses after interferon therapy. Our findings reveal novel putative ATLL driver genes and clinically relevant differences between Japanese and Western ATLL patients.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results